Lenacapavir's 6-Month HIV PrEP Shows Promise, Rollout Gets Mixed Reviews
A twice-yearly injectable PrEP, lenacapavir showed unprecedented efficacy in the PURPOSE 1 and 2 trials, yet its rollout in Uganda is drawing mixed reviews. For health systems, the drug's adherence-friendly profile must clear delivery, access, and stigma barriers to achieve population-level impact.